Showing results (41-50 of 2,507) with videos related to

Sort By:
Pageof 251
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Copy number variations of EphA3 are associated with multiple types of hematologic malignanciesMing Guan, Li Liu, Xiaosu Zhao, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapyStefan Faderl, Deborah Ann Thomas, Susan O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM)Robert A Kyle, Angela Dispenzieri, Shaji Kumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Associated malignancies in patients with Waldenström's macroglobulinemia and their kinChristina Hanzis, Rohit P Ojha, Zachary Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patientsEvangelos Terpos, Anna Tasidou, Evangelos Eleftherakis-Papaiakovou, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Prognostication of the high-risk WM patientEfstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemiaSteven P Treon, Christina Hanzis, Christina Tripsas, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Novel M-component based biomarkers in Waldenström's macroglobulinemiaXavier Leleu, Efstathios Koulieris, Dimitrios Maltezas, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 11, 2021
Oral Azacitidine (CC-486) for the Treatment of Myeloid MalignanciesGuillermo Garcia-Manero, Hartmut Döhner, Andrew H Wei, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 22, 2019
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaJatin Shah, Saad Usmani, Edward A Stadtmauer, et al.
Pageof 251